The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Biomarkers for tuberculosis disease activity, cure, and relapse
Abstract
New drugs, vaccines, and other therapies will be required to realise the goal of global tuberculosis elimination or control. This Review covers the important role biomarkers can have in accelerating drug development by providing validated surrogate endpoints that can bring enhanced statistical power to small short studies. Candidate biomarkers should differentiate people with active tuberculosis from healthy individuals, normalise with therapy, and reproducibly predict clinical outcomes in diverse patient populations. Although a large number of promising candidate biomarkers have been examined to date, few patients in these studies have reached clinically meaningful outcomes, and few of the studies have been conducted to international research standards. These markers must be further studied in tuberculosis treatment trials to evaluate the kinetics of the responses and their relation to long-term clinical outcomes. These studies will benefit from multidisciplinary collaborations including microbiologists, immunologists, clinicians, tuberculosis control personnel, and the pharmaceutical and biotechnology industry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta‐Analysis Of Controlled Clinical Trials
Whitehead, A. (2002) · doi:10.1002/0470854200 · Cited by 827
Interferon-γ and interleukin-12 pathway defects and human disease
Dorman, S. E., & Holland, S. M. (2000) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00010-1 · Cited by 336
Cited by
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Horne, D. J., Royce, S. E., Gooze, L., Narita, M., Hopewell, P. C., Nahid, P., & Steingart, K. R. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70071-2 · Cited by 259
Metadata
- Authors
- Wallis, R. S., Doherty, T. M., Onyebujoh, P., Vahedi, M., Laang, H., Olesen, O., Parida, S., & Zumla, A.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 9
- Issue
- 3
- Pages
- 162-172
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2132657933
- Cited by
- 222
- References
- 2
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers for tuberculosis disease activity, cure, and relapse. https://app.cochat.ai/papers/10.1016/s1473-3099(09)70042-8
- The paper
- Wallis, R. S., Doherty, T. M., Onyebujoh, P., Vahedi, M., Laang, H., Olesen, O., Parida, S., & Zumla, A. (2009). Biomarkers for tuberculosis disease activity, cure, and relapse. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(09)70042-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.